Market Challenges And Opportunities

However, shortages of trained staff and poor quality systems, which results in inefficient screening systems, inadequate procedures for identification, and misidentification of patient or donor blood samples are some of the factors restraining growth of the market.

Blood Screening Market- Drivers

Increasing demand for NAT over ELISA (enzyme-linked immunosorbent assay) test due to high sensitivity and specificity for viral nucleic acid is boosting growth of the blood screening market. For instance, in 2018, Grifols received approval from the U.S. Food & Drug Administration (FDA) for two blood screening assays- Procleix Ultrio Elite and Procleix WNV. Both assays run on the fully automated NAT blood screening platform: Procleix Panther system. The Procleix Panther system with these assays helps blood centers to efficiently screen for infectious diseases and eliminates the need of batch processing.

Increasing number of blood donations campaigns by the government, blood donor agencies, and NGO’s are expected to propel growth of the blood screening market. For instance, according to the WHO reported data in June 2017, around 112.5 million blood donations are collected globally and around half of these are collected in high-income countries, highlighting 19% of the world’s population. Moreover, increase in initiatives by the government to create awareness among the people regarding safety of the donated blood is expected to drive growth of the market. For instance, in 2014, World Health Organization (WHO) recommended to establish a national blood system with well-organized and coordinated blood transfusion services, effective evidence-based and ethical national blood policies, and legislation and regulation that can provide sufficient and timely supplies of safe blood and blood products to meet the transfusion needs of all patients.